安徽多措并举推动药械监管全过程改革

Core Viewpoint - The Anhui Provincial Drug Administration has introduced measures to enhance the regulation of pharmaceuticals and medical devices, aiming to promote high-quality development in the pharmaceutical industry [1][2]. Group 1: Reform Measures - The newly issued measures include 21 specific reform initiatives across five key areas, focusing on supporting drug and medical device research and innovation, as well as the development of traditional Chinese medicine [1]. - Anhui will strengthen tracking services for drug and medical device research, implementing a tailored approach for each company with comprehensive guidance throughout the process [1]. Group 2: Enhancing Approval Processes - The measures aim to improve the efficiency of drug and medical device review and approval processes by enhancing the capabilities of the review team and optimizing the approval workflow [2]. - A tracking service mechanism will be established for key parks, projects, and innovative products to facilitate faster market entry for urgently needed drugs and devices [2]. Group 3: Promoting Industry Compliance - The measures encourage the development of pharmaceutical industry clusters and support the establishment of high-standard specialty industrial parks in regions with existing advantages [2]. - There will be an emphasis on enhancing the regulatory quality of new pharmaceutical distribution models and fostering collaboration in innovative research and development [2].